Home › Research › Biomarkers
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status
Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N et al.. JAMA neurology, 2019-09-01
Topic: Amyloid, tau and blood-test diagnosis
Results The mean (SD) age of the 842 participants in cohort 1 was 72 (5.6) years, with a range of 59 to 88 years, and 446 (52.5%) were female. When adding APOE, the AUC increased significantly to 0.85 (95% CI, 0.82-0.88). The results were similar in CU and cognitively impaired participants, and in younger and older participants.
Key findings
- Results The mean (SD) age of the 842 participants in cohort 1 was 72 (5.6) years, with a range of 59 to 88 years, and 446 (52.5%) were female.
- When adding APOE, the AUC increased significantly to 0.85 (95% CI, 0.82-0.88).
- The results were similar in CU and cognitively impaired participants, and in younger and older participants.
Why it matters
In 842 adults aged 59–88 (average 72, 52.5% women), including people with and without cognitive impairment, researchers tested fully automated blood assays as screening tests for Alzheimer's-related β-amyloid. Combined with APOE gene type, the tests reached an accuracy score (AUC) of 0.85 (95% CI 0.82–0.88), and the results were "similar in CU and cognitively impaired participants, and in younger and older participants." This is a screening-accuracy result for amyloid status, not a dementia diagnosis or a treatment, and the record we hold does not report how the blood tests did without APOE.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants842
- Effect size52.5%; 50.6%
- Evidence strengthModerate
How this study scored 71/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 842 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 434 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 48.2 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 5 / 6 | Cited 36.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 40 other studies in this library |
| Still being cited | 3 / 4 | Cited 161 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31233127) |
| Free to read | 2 / 2 | Free to read |
| Total | 71 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2019.1632
- PubMed: 31233127
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., et al. (2019). Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. JAMA neurology. https://doi.org/10.1001/jamaneurol.2019.1632
Vancouver
Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. JAMA neurology. 2019. doi:10.1001/jamaneurol.2019.1632. PMID: 31233127.
BibTeX
@article{palmqvist2019-31233127,
author = {Palmqvist, S. and Janelidze, S. and Stomrud, E. and Zetterberg, H. and Karl, J. and Zink, K. and Bittner, T. and Mattsson, N. and others},
title = {{Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status}},
journal = {JAMA neurology},
year = {2019},
doi = {10.1001/jamaneurol.2019.1632},
pmid = {31233127},
url = {https://doi.org/10.1001/jamaneurol.2019.1632}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Later studies that cite this one
40 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Biomarkers
Also tagged “biomarkers”
821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.